Macerich

From The Pages Of The American Lawyer: The Ugly Battle Over Botox

From The Pages Of The American Lawyer: The Ugly Battle Over Botox

Toward the end of the Boston marathon last April 21, the only thing keeping Cary Hyden going was the promise of a hot shower, a nap and, he says, a “decent restaurant meal.” But that was not to be. When Hyden, head of Latham & Watkins’ Orange County corporate group, got to his hotel room, he found several missed calls from his partner Paul Tosetti. Longtime client Allergan Inc., maker of the anti-wrinkle drug Botox, had received a $45.6 billion cash-and-stock offer from Canada’s Valeant Pharmaceuticals Inc.

Allergan, a company with little long-term debt and an active research and development program, wanted no part of Valeant, which mostly grew by...

51°